Skip to main content
SpringerLink
Log in

Pediatric Mastocytosis: Recognition and Management

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Mastocytosis is a heterogeneous group of disorders characterized by the accumulation of clonal mast cells in organs such as the skin and bone marrow. In contrast to adults, most affected children have only cutaneous involvement. This article reviews the molecular pathogenesis, skin findings, mast cell mediator-related symptoms, evaluation, and management of childhood-onset mastocytosis, noting differences from adult-onset disease. Current classification of cutaneous mastocytosis and the natural histories of different variants in pediatric patients are highlighted, with a focus on clinical manifestations with prognostic implications. A practical algorithm is provided to guide clinical assessment, laboratory and other investigations, and longitudinal monitoring, including recognition of hepatosplenomegaly as a marker of systemic disease and utilization of allele-specific quantitative PCR (ASqPCR) to detect KIT mutations in the peripheral blood. Updated information and consensus-based recommendations regarding possible triggers of mast-cell degranulation (e.g., physical, medications) are discussed, with an emphasis on patient-specific factors and avoiding excessive parental concern. Lastly, an individualized, stepwise approach to treatment of symptoms, skin-directed therapy, and potential use of kinase inhibitors for severe systemic disease is outlined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Horny HP, Akin C, Metcalfe DD, et al. Mastocytosis (mast cell disease). In: Swerdlow SH, Campo PE, Harris NL, et al., editors. World Health Organization (WHO) classification of tumours: pathology and genetics of tumours of the haematopoietic and lymphoid tissues, vol. 2. Lyon (France): IARC Press; 2008. p. 54–63.

    Google Scholar 

  2. Valent P, Akin C, Dean D. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017;129:1420–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Akin C, Valent P. Diagnostic criteria and classification of mastocytosis in 2014. Immunol Allergy Clin N Am. 2014;34:207–18.

    Google Scholar 

  4. Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137:35–45.

    PubMed  Google Scholar 

  5. Heide R, Tank B, Oranje AP. Mastocytosis in childhood. Pediatr Dermatol. 2002;19:375–81.

    PubMed  Google Scholar 

  6. Wiechers T, Rabenhorst A, Schick T, et al. Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. J Allergy Clin Immunol. 2015;136:1581–90.

    PubMed  Google Scholar 

  7. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

    CAS  PubMed  Google Scholar 

  8. Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res. 2001;25:519–28.

    CAS  PubMed  Google Scholar 

  9. Hannaford R, Rogers M. Presentation of cutaneous mastocytosis in 173 children. Australas J Dermatol. 2001;42:15–21.

    CAS  PubMed  Google Scholar 

  10. Middelkamp Hup MA, Heide R, Tank B, et al. Comparison of mastocytosis with onset in children and adults. J Eur Acad Dermatol Venereol. 2002;16:115–20.

    CAS  PubMed  Google Scholar 

  11. Kiszewski AE, Duran-Mckinster C, Orozco-Covarrubias L, et al. Cutaneous mastocytosis in children: a clinical analysis of 71 cases. J Eur Acad Dermatol Venereol. 2004;18:285–90.

    CAS  PubMed  Google Scholar 

  12. Ben-Amitai D, Metzker A, Cohen HA. Pediatric cutaneous mastocytosis: a review of 180 patients. Isr Med Assoc J. 2005;7:320–2.

    PubMed  Google Scholar 

  13. Alvarez-Twose I, Vañó-Galván S, Sánchez-Muñoz L, et al. Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy. 2012;67:813–21.

    CAS  PubMed  Google Scholar 

  14. Lange M, Niedoszytko M, Renke J, et al. Clinical aspects of paediatric mastocytosis: a review of 101 cases. J Eur Acad Dermatol Venereol. 2013;27:97–102.

    CAS  PubMed  Google Scholar 

  15. Méni C, Georgia-Lavialle S, de Peufeilhoux LLS, et al. Pediatric mastocytosis: long-term follow up of 53 patients with whole sequencing of KIT. A prospective study. Br J Dermatol. 2018;179:925–32.

    PubMed  Google Scholar 

  16. Leszczynska M, Kwon C, Juarez M, et al. Cutaneous mastocytosis in a pediatric population: clinical features and long-term follow-up. In: Poster, Society of Pediatric Dermatology Annual Meeting, July 2019

  17. Bodemer C, Hermine O, Palmérini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol. 2010;130:804–15.

    CAS  PubMed  Google Scholar 

  18. Méni C, Bruneau J, Georgin-Lavialle S, et al. Paediatric mastocytosis: a systematic review of 1747 cases. Br J Dermatol. 2015;172:642–51.

    PubMed  Google Scholar 

  19. Arase N, Wataya-Kaneda M, Murota H, et al. Genotype and phenotype analysis of patients with pediatric cutaneous mastocytosis, especially wild-type KIT patients. J Dermatol. 2020;47:426–9.

    CAS  PubMed  Google Scholar 

  20. Ma D, Stence AA, Bossler AB, et al. Identification of KIT activating mutations in paediatric solitary mastocytoma. Histopathology. 2014;64:218–25.

    PubMed  Google Scholar 

  21. Polivka L, Rossignol J, Neuraz A, et al. Criteria for the regression of pediatric mastocytosis: a long-term follow-up. J Allergy Clin Immunol Pract. 2020. https://doi.org/10.1016/j.jaip.2020.12.019.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Tang X, Boxer M, Drummond A, et al. A germline mutation in KIT In familial diffuse cutaneous mastocytosis. J Med Genet. 2004;41:e88.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Wang HJ, Lin ZM, Zhang J, et al. A new germline mutation in KIT associated with diffuse cutaneous mastocytosis in a Chinese family. Clin Exp Dermatol. 2014;39:146–9.

    PubMed  Google Scholar 

  24. Caplan RM. The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases. Arch Dermatol. 1963;87:146–57.

    CAS  PubMed  Google Scholar 

  25. Brockow K, Akin C, Huber M, Metcalfe DD. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol. 2003;48:508–16.

    PubMed  Google Scholar 

  26. Hartmann K, Henz BM. Classification of cutaneous mastocytosis: a modified consensus proposal. Leuk Res. 2002;26:483–4.

    PubMed  Google Scholar 

  27. Gurnee E, Johansen MJ, Phung TL, et al. Pediatric maculopapular cutaneous mastocytosis: retrospective review of signs, symptoms, and associated conditions. Pediatr Dermatol. 2020. https://doi.org/10.1111/pde.14399.

    Article  PubMed  Google Scholar 

  28. Heinze A, Kuemmet TJ, Chiu YE, Galbraith SS. Longitudinal study of pediatric urticaria pigmentosa. Pediatr Dermatol. 2017;34:144–9.

    PubMed  Google Scholar 

  29. Uzzaman A, Maric I, Noel P, et al. Pediatric-onset mastocytosis: a long-term follow-up and correlation with bone marrow histopathology. Pediatr Blood Cancer. 2009;53:629–34.

    PubMed  PubMed Central  Google Scholar 

  30. Broesby-Olsen S, Dybedal I, Gulen T, et al. Multidisciplinary management of mastocytosis: Nordic Expert Group Consensus. Acta Derm Venereol. 2016;96:602–12.

    PubMed  Google Scholar 

  31. Lanternier F, Cohen-Akenine A, Palmerini F, et al. Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS ONE. 2008;3:e1906.

    PubMed  PubMed Central  Google Scholar 

  32. Matito A, Azaña J, Torrelo A, Alvarez-Twose I. Cutaneous mastocytosis in adults and children: new classification and prognostic factors. Immunol Allergy Clin N Am. 2018;38:351–63.

    Google Scholar 

  33. Kleewein K, Lang R, Diem A, et al. Diffuse cutaneous mastocytosis masquerading as epidermolysis bullosa. Pediatr Dermatol. 2011;28:720–5.

    PubMed  Google Scholar 

  34. Lange M, Niedoszytko M, Nedoszytko B, et al. Diffuse cutaneous mastocytosis: analysis of 10 cases and a brief review of the literature. J Eur Acad Dermatol Venereol. 2012;26:1565–71.

    CAS  PubMed  Google Scholar 

  35. Hosking AM, Makdisi J, Ortenzio F, et al. Diffuse cutaneous mastocytosis: case report and literature review. Pediatr Dermatol. 2018;35:e348–52.

    PubMed  Google Scholar 

  36. Jenkinson H, Lundgren A, Carter M, et al. Management of a neonate with diffuse cutaneous mastocytosis: case report and literature review. Pediatr Dermatol. 2019;36:486–9.

    PubMed  Google Scholar 

  37. Chaudhary N, Shapiro N, Bhutada A, Rastogi S, et al. c-KIT-Positive fatal diffuse cutaneous mastocytosis with systemic manifestations in a neonate. J Pediatr Hematol Oncol. 2019;41:e338–40.

    PubMed  Google Scholar 

  38. Hudson A, Finlayson L. Diffuse cutaneous bullous mastocytosis and disseminated intravascular coagulation postvaccination: a case report. J Cutan Med Surg. 2016;20:596–9.

    PubMed  Google Scholar 

  39. Leung A, Lam J, Leong K. Childhood solitary cutaneous mastocytoma: clinical manifestations, diagnosis, evaluation and management. Curr Pediatr Rev. 2019;15:42–6.

    PubMed  PubMed Central  Google Scholar 

  40. Azaña JM, Velasco E, Torrelo A, et al. Mastocitomas: revision de 33 casos infantiles. Actas Dermosifiliogr. 1993;84:559–62.

    Google Scholar 

  41. Requena López S, Matito A, Alvarez-Twose I, Torrelo A. Perioperative anaphylaxis in a patient with a solitary mastocytoma. Pediatr Dermatol. 2019;36:352–4.

    PubMed  Google Scholar 

  42. Cheng YP, Hsiao CH, Dai YS. Nevoid urticaria pigmentosa along Blaschko’s lines. J Dermatol. 2012;39:665–6.

    PubMed  Google Scholar 

  43. Merika EE, Bunker CB, Francis N, et al. A segmental rash in a young male: a quiz. Naevoid urticaria pigmentosa. Acta Derm Venereol. 2014;94:253–4.

    PubMed  Google Scholar 

  44. Ahn H, Park H, Jeong K, et al. Atypical maculopapular cutaneous mastocytosis showing a nevus spilus-like lesion. Pediatr Dermatol. 2018;35:E306–7.

    PubMed  Google Scholar 

  45. Tsutsui Y, Koga M, Koga K, Imafuku S. Child case of linear variant of telangiectasia macularis eruptive perstans. J Dermatol. 2019;46:e469–70.

    PubMed  Google Scholar 

  46. Vano-Galvan S, Alvarez-Twose I, De las Heras E, et al. Dermoscopic features of skin lesions in patients with mastocytosis. Arch Dermatol. 2011;147:932–40.

    PubMed  Google Scholar 

  47. Azaña JM, Torrelo A, Mediero IG, Zambrano A, et al. Urticaria pigmentosa: a review of 67 pediatric cases. Pediatr Dermatol. 1994;11:102–6.

    PubMed  Google Scholar 

  48. Barnes M, Van L, DeLong L, et al. Severity of cutaneous findings predict the presence of systemic symptoms in pediatric maculopapular cutaneous mastocytosis. Pediatr Dermatol. 2014;31:271–5.

    PubMed  Google Scholar 

  49. Gurnee E, Phung T, Guo E, et al. Neurocognitive dysfunction and anaphylaxis in pediatric maculopapular cutaneous mastocytosis. J Allergy Clin Immunol. 2020;8:409–10.

    Google Scholar 

  50. Czarny J, Lange M, Lugowska-Umer H, Nowicki RJ. Cutaneous mastocytosis treatment: strategies, limitations, and perspectives. Postepy Dermatol Alergol. 2018;6:541–5.

    Google Scholar 

  51. de Olano GD, de la Hoz B, Nunez-Lopez R, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy. 2007;37:1547–55.

    Google Scholar 

  52. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy. 2008;63:226–32.

    CAS  PubMed  Google Scholar 

  53. Matito A, Carter M. Cutaneous and systemic mastocytosis in children: a risk factor for anaphylaxis? Curr Allergy Asthma Rep. 2015;15:22.

    CAS  PubMed  Google Scholar 

  54. Theoharides TC. Autism spectrum disorders and mastocytosis. Int J Immunopathol Pharmacol. 2009;22:642–51.

    Google Scholar 

  55. Seamens A, Taussig B, Penziner K, et al. Exploring the prevalence of learning disabilities in children with cutaneous mastocytosis: a pilot cohort study. J Am Acad Dermatol. 2016;75:1254–5.

    PubMed  Google Scholar 

  56. Hemati P, Revah-Politi A, Bassan H, et al. Refining the phenotype associated with GNB1 mutations: clinical data on 18 newly identified patients and review of the literature. Am J Med Genet A. 2018;176:2259–75.

    CAS  PubMed  Google Scholar 

  57. Alvarez-Twose I, Jara-Acevedo M, Morgado JM, et al. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol. 2016;137:168-178e1.

    CAS  PubMed  Google Scholar 

  58. Chan EC, Bai U, Kirshenbaum AS, et al. Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype. J Allergy Clin Immunol. 2014;134:178–87.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Greenberger S, Landov H, Confino Y, et al. Immunophenotype of pediatric-onset mastocytosis does not correlate with clinical course. Pediatr Dermatol. 2019;36:477–81.

    PubMed  Google Scholar 

  60. de Paiva Silva RG, Tournier E, Sarian LO, et al. Prevalence of CD30 immunostaining in neoplastic mast cells: a retrospective immunohistochemical study. Medicine (Baltimore). 2018;97:e10642.

    Google Scholar 

  61. Van Anrooij B, Kluin PM, Oude Elberink JNG, et al. CD30 in systemic mastocytosis. Immunol Allergy Clin N Am. 2014;34:341–55.

    Google Scholar 

  62. Hollmann TJ, Brenn T, Hornick JL. CD25 expression on cutaneous mast cells from adult patients presenting with urticaria pigmentosa is predictive of systemic mastocytosis. Am J Surg Pathol. 2008;32:139–45.

    PubMed  Google Scholar 

  63. Lange M, Zawrocki A, Nedoszytko B, et al. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin? Int Arch Allergy Immunol. 2014;165:104–10.

    CAS  PubMed  Google Scholar 

  64. Poirier E, Fraitag S, du Montcel TS, et al. CD30 expression in cutaneous lesions of systemic mastocytosis: clinical, biological, and histopathological analysis of 27 patients. JEADV. 2019;33:e310–47.

    Google Scholar 

  65. Carter M, Clayton S, Komarow H, et al. Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis. J Allergy Clin Immunol. 2015;136:1673–9.

    PubMed  PubMed Central  Google Scholar 

  66. Lange M, Zawadzka A, Schrörs S, et al. The role of serum tryptase in the diagnosis and monitoring of pediatric mastocytosis: a single center experience. Postepy Dermatol Alergol. 2017;34:306–12.

    PubMed  PubMed Central  Google Scholar 

  67. Seth N, Chinen J, Buheis G, et al. Serum tryptase levels in pediatric mastocytosis and association with systemic symptoms. Ann Allergy Asthma Immunol. 2020;125:219–21.

    CAS  PubMed  Google Scholar 

  68. Carter M, Bai Y, Ruiz Esteves K, et al. Detection of KIT D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease. Br J Haematol. 2018;183:775–82.

    CAS  PubMed  Google Scholar 

  69. Czarny J, Zuk M, Zawrocki Z, et al. New approach to paediatric mastocytosis: implications of KIT D816V mutation detection in peripheral blood. Acta Derm Venereol. 2020;100:adv00149.

    CAS  PubMed  Google Scholar 

  70. Hussain SH. Pediatric mastocytosis. Curr Opin Pediatr. 2020;32:531–8.

    PubMed  Google Scholar 

  71. Renke J, Lange M, Dawicka J, et al. Hypogammaglobulinemias in infants and toddlers with mastocytosis – a new aspect to analyze? Pediatr Allergy Immunol. 2016;27:331–2.

    PubMed  Google Scholar 

  72. Ertugrul B, Ozturk K, Gurkan O, Ertugrul A. Pediatric cutaneous mastocytosis and c-KIT mutation screening. Allergy Asthma Proc. 2019;40:123–8.

    PubMed  Google Scholar 

  73. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435–53.

    CAS  PubMed  Google Scholar 

  74. Azaña JM, Torrelo A, Matito A. Update on mastocytosis (part 2): categories, prognosis, and treatment. Actas Dermosifiliogr. 2016;107:15–22.

    PubMed  Google Scholar 

  75. Siebenhaar F, Akin C, Bindslev-Jensen C, et al. Treatment strategies in mastocytosis. Immunol Allergy Clin N Am. 2014;34:433–47.

    Google Scholar 

  76. Carter MC, Metcalfe DD, Matito A, et al. Adverse reactions to drugs and biologics in patients with clonal mast cell disorders: a group report of the Mast Cells Disorder Committee, American Academy of Allergy and Immunology. J Allergy Clin Immunol. 2019;143:880–93.

    PubMed  Google Scholar 

  77. Ahmad N, Evans P, Lloyd-Thomas AR. Anesthesia in children with mastocytosis—a case based review. Paediatr Anaesth. 2009;19:97–107.

    PubMed  Google Scholar 

  78. Sánchez-Matas I, Matito A, de Olano GD, et al. Prevalence of hypersensitivity reactions to nonsteroidal anti-inflammatory drugs in 212 patients with mastocytosis in Spain. Allergy. 2009;64:551.

    Google Scholar 

  79. Carter MC, Uzzaman A, Scott LM. Pediatric mastocytosis: routine anesthetic management of a complex disease. Anesth Analg. 2008;107:422–7.

    PubMed  PubMed Central  Google Scholar 

  80. Klein NJ, Misseldine S. Anesthetic considerations in pediatric mastocytosis: a review. J Anesth. 2013;27:588–98.

    PubMed  Google Scholar 

  81. Hermans MAW, et al. Management around invasive procedures in mastocytosis: an update. Ann Allergy Asthma Immunol. 2017;119:304–9.

    PubMed  Google Scholar 

  82. James PD, Krafchik BR, Johnston AE. Cutaneous mastocytosis in children: anaesthetic considerations. Can J Anaesth. 1987;34:522–4.

    CAS  PubMed  Google Scholar 

  83. Matito A, Morgado JM, Sanchez-Lopez P, et al. Management of anesthesia in adult and pediatric mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) based on 726 anesthetic procedures. Int Arch Allergy Immunol. 2015;167:47–56.

    CAS  PubMed  Google Scholar 

  84. Dewachter P, Castells MC, Hepner DL, Mouton-Faivre C. Perioperative management of patients with mastocytosis. Anesthesiology. 2014;120:753–9.

    PubMed  Google Scholar 

  85. Parente R, Pucino V, Magliacane D, et al. Evaluation of vaccination safety in children with mastocytosis. Pediatr Allergy Immunol. 2017;28:93–5.

    PubMed  Google Scholar 

  86. Vlieg-Boerstra BJ, van der Heide S, Oude Elberink JNG, et al. Mastocytosis and adverse reactions to biogenic amines and histamine-releasing foods: what is the evidence? Neth J Med. 2005;63:244–9.

    CAS  PubMed  Google Scholar 

  87. Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr. 2007;85:1185–96.

    CAS  PubMed  Google Scholar 

  88. Russell N, Jennings S, Jennings B, et al. The Mastocytosis Society survey on mast cell disorders: part 2—patient clinical experiences and beyond. J Allergy Clin Immunol Pract. 2019;7:1157–65.

    PubMed  Google Scholar 

  89. Jarkvist J, Brockow K, Gülen T. Low frequency of IgE-mediated food hypersensitivity in mastocytosis. J Allergy Clin Immunol Pract. 2020;8:3093–101.

    PubMed  Google Scholar 

  90. Alvarez-Twose I, de Olano GD, Sanchez-Munoz L, et al. Clinical, biological and molecular characteristics of systemic mast cell disorders presenting with severe mediator-related symptoms. J Allergy Clin Immunol. 2010;125:1269–78.

    CAS  PubMed  Google Scholar 

  91. Bonadonna P, Scaffidi L. Hymenoptera anaphylaxis as a clonal mast cell disorder. Immunol Allergy Clin N Am. 2018;38:455–68.

    Google Scholar 

  92. Dölle-Bierke S, Siebenhaar F, Burmeister T, Worm M. Detection of KIT D816V mutation in patients with severe anaphylaxis and normal basal tryptase-first data from the Anaphylaxis Registry (NORA). J Allergy Clin Immunol. 2019;144(1448–50):e1.

    Google Scholar 

  93. Yavuz ST, Sackensen C, Sahiner UM, et al. Importance of serum basal tryptase levels in children with insect venom allergy. Allergy. 2013;68:386–91.

    CAS  PubMed  Google Scholar 

  94. Smith J, Murphy M, Funk T, et al. Epinephrine auto-injector for urticaria pigmentosa: a retrospective cohort study. In: Presented at Society of Pediatric Dermatology Annual Meeting, July 2019.

  95. Greenhawt M, Gupta RS, Meadows JA, et al. Guiding principles for the recognition, diagnosis, and management of infants with anaphylaxis: an expert panel consensus. J Allergy Clin Immunol Pract. 2019;7:1148–56.

    PubMed  Google Scholar 

  96. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393–414.

    CAS  PubMed  Google Scholar 

  97. Sarti L, Barni S, Giovannini M, et al. 80c. Efficacy and tolerability of the updoing of second-generation non-sedation H1 antihistamines in children with chronic spontaneous urticaria. Pediatr Allergy Immunol. 2020. https://doi.org/10.1111/pai.13325.

    Article  PubMed  Google Scholar 

  98. Turner PJ, Kemp AS, Rogers M, Mehr S. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol. 2012;29:222–3.

    PubMed  Google Scholar 

  99. Edwards AM, Capková S. Oral and topical sodium cromoglicate in the treatment of diffuse cutaneous mastocytosis in an infant. BMJ Case Rep. 2011;29:bcr0220113910.

    Google Scholar 

  100. Vieira Dos Santos R, Magerl M, Martus P, et al. Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. Br J Dermatol. 2010;162:674–6.

    CAS  PubMed  Google Scholar 

  101. Sokol KC, Ghazi A, Kelly BC, et al. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin Immunol Pract. 2014;2:266–70.

    PubMed  Google Scholar 

  102. Jendoubi F, Gaudenzio N, Gallini A, et al. Omalizumab in the treatment of adult patients with mastocytosis: a systematic review. Clin Exp Allergy. 2020;50:654–61.

    CAS  PubMed  Google Scholar 

  103. Hughes J, Olynyc T, Chapdelaine H, et al. Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair(R)). Clin Exp Dermatol. 2018;43:573–6.

    CAS  PubMed  Google Scholar 

  104. Distler M, Maul JT, Steiner UC, et al. Efficacy of omalizumab in mastocytosis: allusive indication obtained from a prospective, double-bline, multicenter study (XOLIMA study). Dermatology. 2020;20:1–11.

    Google Scholar 

  105. Yankova R, Abadjieva T, Belovezhdov V. Cutaneous mastocytosis with persistent blistering: successful treatment with methylprednisolone and 3-year follow-up management. Dermatol Ther (Heidelb). 2015;5:145–50.

    PubMed  PubMed Central  Google Scholar 

  106. Ma Z, Tovar JP, Kwong KYC, Paek D. Pimecrolimus induces apoptosis of mast cells in a murine model of cutaneous mastocytosis. Int Arch Allergy Immunol. 2010;153:413–8.

    CAS  PubMed  Google Scholar 

  107. Mashiah J, Harel A, Bodemer C, et al. Topical pimecrolimus for paediatric cutaneous mastocytosis. Clin Exp Dermatol. 2018;43:559–65.

    CAS  PubMed  Google Scholar 

  108. Patrizi A, Tabanelli M, Neri I, Virdi A. Topical corticosteroids versus “wait and see” in the management of solitary mastocytoma in pediatric patients: a long-term follow-up. Dermatol Ther. 2015;28:57–61.

    PubMed  Google Scholar 

  109. Mateo JR. Mastocytoma: topical corticosteroid treatment. J Eur Acad Dermatol Venereol. 2001;15:492–4.

    CAS  PubMed  Google Scholar 

  110. Barton J, Lavker RM, Schechter NM, Lazarus GS. Treatment of urticaria pigmentosa with corticosteroids. Arch Dermatol. 1985;121:1516–23.

    CAS  PubMed  Google Scholar 

  111. Yung A. Flushing due to solitary cutaneous mastocytoma can be prevented by hydrocolloid dressings. Pediatr Dermatol. 2004;21:262–4.

    PubMed  Google Scholar 

  112. Brazzelli V, Grassi S, Merante S, et al. Narrow-band UVB phototherapy and psoralen-ultraviolet A photochemotherapy in the treatment of cutaneous mastocytosis: a study in 20 patients. Photodermatol Photoimmunol Photomed. 2016;32:238–46.

    CAS  PubMed  Google Scholar 

  113. Kinsler VA, Hawk JL, Atherton DJ. Diffuse cutaneous mastocytosis treated with psoralen photochemotherapy: case report and review of the literature. Br J Dermatol. 2005;152:179–80.

    CAS  PubMed  Google Scholar 

  114. Piris-Villaespesa M, Alvarez-Twose I. Systemic mastocytosis: following the tyrosine kinase inhibition roadmap. Front Pharmacol. 2020;11:443.

    CAS  PubMed  PubMed Central  Google Scholar 

  115. Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374:2530–41.

    CAS  PubMed  Google Scholar 

  116. Liu M, Kohn L, Roach G, et al. Treatment of systemic mastocytosis in an infant with midostaurin. J Allergy Clin Immunol Pract. 2019;7(2929–31):e1.

    Google Scholar 

  117. Morren MA, Hoppé A, Renard M, et al. Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis. J Pediatr. 2013;162:205–7.

    PubMed  Google Scholar 

  118. Hoffmann KM, Moser A, Lohse P, et al. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood. 2008;112:1655–7.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Dermatology, Hackensack Meridian School of Medicine at Seton Hall University, 155 Polifly Road, Suite 101, Hackensack, NJ, 07601, USA

    Julie V. Schaffer

Authors
  1. Julie V. Schaffer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julie V. Schaffer.

Ethics declarations

Funding

None.

Conflicts of interest/competing interests

None.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent to publish

Not applicable.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Author contributions

JS designed the article, performed the literature search and data analysis, drafted and critically revised the work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schaffer, J.V. Pediatric Mastocytosis: Recognition and Management. Am J Clin Dermatol 22, 205–220 (2021). https://doi.org/10.1007/s40257-020-00581-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-020-00581-5

Search

Navigation